{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By PETER J. HENNING", "person": [{"middlename": "J.", "firstname": "Peter", "lastname": "HENNING", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": null, "type_of_material": "News", "word_count": "1152", "lead_paragraph": "A judge\u2019s decision sets up a likely court battle to determine just how far the government can go to punish speech that is truthful.", "pub_date": "2015-08-11T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A.\u2019s \u2018Off-Label\u2019 Drug Policy Leads to Free-Speech Fight", "content_kicker": "White Collar Watch", "kicker": "White Collar Watch"}, "snippet": "A judge\u2019s decision sets up a likely court battle to determine just how far the government can go to punish speech that is truthful.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/08/11/business/dealbook/fdas-off-label-drug-policy-leads-to-free-speech-fight.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Engelmayer, Paul A", "name": "persons"}, {"rank": "2", "is_major": "N", "value": "Freedom of Speech and Expression", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Amarin Corp PLC", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Suits and Litigation (Civil)", "name": "subject"}], "blog": [], "_id": "55c8ec0738f0d87d6b06f1b4", "source": "The New York Times"}